

Special Issue

BCMA-Directed CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Message from the Guest Editor

Relapsed or refractory multiple myeloma poses a significant challenge in hematology. BCMA-directed CAR-T therapy has emerged as a promising treatment approach in such cases. This specialized immunotherapy targets the B-cell maturation antigen (BCMA) expressed on myeloma cells, providing a targeted and potentially curative option. However, challenges such as cytokine release syndrome and neurotoxicity persist, requiring careful patient monitoring and management. This Special Issue will explore the latest advancements, outcomes, and challenges in BCMA-directed CAR-T therapy for multiple myeloma, facilitating a deeper understanding of its potential in transforming the landscape of myeloma treatment.

Guest Editor

Dr. Al-Ola A. Abdallah

Division of Hematologic Malignancies & Cellular Therapeutics,
University of Kansas Medical Center, Westwood, KS 66205, USA

Deadline for manuscript submissions

30 September 2025



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/228659

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)